Role of chemotherapy in clinical T2N0M0 gastric cancer.

Authors

Sawyer Bawek

Sawyer Bawek

University at Buffalo, Department of Internal Medicine, Buffalo, NY;

Sawyer Bawek , Yeshwanth Vedire , Adrienne Groman , Sarbajit Mukherjee

Organizations

University at Buffalo, Department of Internal Medicine, Buffalo, NY; , Roswell Park Comprehensive Cancer Center, Buffalo, NY; , Roswell Park Cancer Institute, Department of Cancer Prevention and Population Sciences, Buffalo, NY;

Research Funding

Other
This work was supported by Roswell Park Comprehensive Cancer Center and National Cancer Institute (NCI) grant, P30CA016056

Background: The role of chemotherapy for patients with early stage, node-negative gastric adenocarcinoma (T2N0M0) remains unclear. Possible options are surgery alone, surgery followed by adjuvant chemotherapy, or perioperative chemotherapy. The objective of our study was to investigate the role and sequence of chemotherapy in T2N0M0 gastric adenocarcinoma. Methods: The National Cancer Data Base (2006-2017) was used to identify patients with T2N0M0 gastric adenocarcinoma. Patients were categorized into 3 groups, surgery alone (S), surgery followed by adjuvant chemotherapy (AC), and peri-operative chemotherapy (POC). Univariate and multivariable Cox proportional-hazards models were performed to evaluate treatment differences in overall survival (OS). Patients were further sub-categorized into two subgroups based on the number of regional nodes examined, less than 15 (RNE<15) and greater or equal to 15 (RNE>15). Univariate and multivariable Cox proportional-hazards models were performed on each subgroup to assess the treatment differences within two groups. Results: The retrospective study analyzed 3,142 patients between 2006 to 2017. Surgery alone represented 2,090 patients (66.5%), AC group had 360 patients (11.5%), and the POC group 692 patients (22.0%). The median age of the population was 70 yrs. Mean inpatient stay was 12.5 days in S, 9.2 days in AC and 10.1 days in the POC group (p<0.001). In the multivariable model, surgery followed by adjuvant chemotherapy (HR 0.75, p=0.003), RNE>15 (HR 0.73, p<0.001), patients treated at academic facilities (HR 0.84, p=0.005), female sex (HR 0.84, p=0.004), and Asian race (HR 0.69, p=0.002) had better outcomes. There were 1,526 (49.2%) patients with RNE<15 and 1,577 (50.8%) patients with RNE>15. Subgroup analysis showed that peri-operative chemotherapy for RNE<15 was beneficial (HR 0.74, p= 0.029). Patients with RNE>15 had an improved survival with surgery followed by adjuvant chemotherapy (HR 0.72, p= 0.017) in the multivariable model. Conclusions: Surgery followed by adjuvant chemotherapy was found to be beneficial in patients having a T2N0M0 Gastric Cancer. However, the number of lymph nodes examined during surgery influences this association. Perioperative chemotherapy maybe beneficial for patients who were under staged due to inadequate exploration of lymph nodes during surgery.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 308)

DOI

10.1200/JCO.2023.41.4_suppl.308

Abstract #

308

Poster Bd #

C7

Abstract Disclosures

Similar Abstracts

First Author: So Heun Lee

First Author: Marytere Herrera

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Role of adjuvant chemotherapy in patients with stage II-III ampullary cancer.

First Author: Nikolay Semenov